Canine
Update (July 5, 2026): Superficial Keratectomy for SCCED in Dogs — 99% Single-Procedure Healing (Irving 2025)
Bottom line
- In 107 dogs (121 SCCEDs), superficial keratectomy achieved 99% (120/121) healing within 21 days with zero postoperative complications — the highest single-procedure closure rate reported for this lesion [1].
- Diamond-burr debridement (DBD) remains the standard of care but heals ~67–77% of eyes after one treatment; adding a grid keratotomy does not improve outcomes over DBD alone [2][3].
- This is uncontrolled retrospective evidence from a specialist referral setting — treat it as a signal that keratectomy is a high-yield salvage/first-line option in trained hands, not as a mandate to abandon DBD in general practice.
Clinical facts
- What a SCCED is. A spontaneous chronic corneal epithelial defect (SCCED; boxer ulcer, indolent ulcer, refractory corneal erosion) is a superficial, non-infected ulcer that fails to re-epithelialize because a redundant, non-adherent epithelial lip cannot bond to an abnormal anterior stromal layer. It is a defect of adhesion, not of infection or depth.
- Why simple debridement is not enough. Cotton-tipped debridement alone removes the loose epithelium but leaves the aberrant stromal surface, so recurrence is common. The established mechanical solutions — grid/punctate keratotomy, DBD, and superficial keratectomy — all work by disrupting or removing that abnormal anterior stroma to create an adherable bed.
- Superficial keratectomy removes a thin lamella of anterior stroma (roughly one-fifth corneal depth in the anchor study) under operating-microscope guidance, followed by a bandage contact lens [1]. It is the most aggressive of the three and has historically been reserved for DBD/keratotomy failures because it requires magnification, sedation or general anesthesia, and surgical skill.
- The comparators. DBD is a rotary burr that abrades non-adherent epithelium and superficial stroma chairside; grid keratotomy scores the stroma with a needle. Both are widely performed in general practice.
For a case-specific read on whether keratectomy, DBD, or continued medical management fits a given patient, ask Voyage ForVets about this study.
What the evidence shows
Anchor study — Irving et al., Veterinary Ophthalmology 2025 [1]. This multi-surgeon retrospective evaluated superficial keratectomy in 107 dogs with 121 SCCEDs (mean age 8.3 years). Keratectomy was performed to approximately one-fifth of corneal depth under the operating microscope, with a bandage lens placed immediately and healing assessed by fluorescein staining. Ninety-nine percent (120/121) of SCCEDs healed with no additional treatment within 21 days, and the single non-healing eye closed two weeks after a Day-14 DBD. Critically, no postoperative complications were noted — no perforation, infection, or clinically significant scarring reported in the cohort. That combination of near-universal single-procedure closure and an absent complication signal is what makes the paper notable.
Supporting evidence — DBD outcomes. The benchmark to beat is DBD, and the largest randomized-comparison data come from Wu et al. 2018 (194 dogs): DBD alone healed 77.4% (82/106) of eyes after the first treatment (mean 13.3 ± 4.9 days) and DBD + superficial grid keratotomy healed 77.3% (68/88) (mean 15.4 ± 5.0 days), with no significant difference between techniques (P = 1) and a 13.3% complication rate in single-treatment eyes [2]. A more recent large retrospective, McKeever et al. 2026 (521 dogs, 598 eyes), reported a lower real-world single-DBD success of 67.7% (405/598), with French bulldogs showing reduced odds of normal healing [3]. Across the DBD literature, first-pass healing clusters in the high-60s to low-90s percent depending on case mix and recheck timing.
How to read the delta. The 99% keratectomy figure sits above the DBD range, and the reported complication rate is lower — but the comparison is indirect. Irving 2025 and the DBD studies are separate retrospective cohorts with different populations, surgeons, and follow-up windows; there is no head-to-head randomized trial of keratectomy versus DBD. The keratectomy series also reflects specialist referral practice with microscope access, which self-selects for technique quality.
How this fits clinical practice
- DBD stays first-line in general practice. It is chairside, requires no microscope, heals two-thirds to three-quarters of eyes on the first pass, and its failures are recoverable [2][3]. Nothing in the anchor study displaces it as the pragmatic starting point for most clinicians.
- Skip the grid. The Wu data show adding a superficial grid keratotomy to DBD confers no healing advantage and no complication penalty, so the extra step is hard to justify on evidence [2]. Recurrent-ulcer protocols that still default to DBD + grid should be revisited.
- Position keratectomy as the high-yield escalation. For DBD failures — or as a primary option where operating-microscope surgery is available — superficial keratectomy offers the best-documented single-procedure closure rate in the current literature [1]. The near-zero complication signal, if it holds in prospective work, weakens the traditional "reserve it because it's risky" argument.
- Set expectations by signalment. Breed matters: French bulldogs healed less reliably and had more complications after DBD in the 2026 cohort, a useful prognostic flag when counseling owners and choosing between chairside and surgical approaches [3].
- What is still missing. No randomized keratectomy-versus-DBD trial exists, complication reporting is retrospective, and long-term scarring/visual outcomes are not systematically compared. The 99% number is a strong hypothesis-generator, not level-1 proof.
Want the comparison mapped onto a specific presentation — breed, prior DBD attempts, equipment on hand? Ask Voyage ForVets to work through the options.
This brief summarizes published evidence for veterinary professionals and does not replace individual clinical judgment, hands-on ophthalmic assessment, or referral where indicated.
References
- Irving W, McCarthy P, Reynolds B, Whittaker C, Caruso K, Smith J, Annear M. Superficial keratectomy for the treatment of spontaneous chronic corneal epithelial defects in dogs. Veterinary Ophthalmology. 2025;28(2):275-280. https://pubmed.ncbi.nlm.nih.gov/38468142/
- Wu D, Smith SM, Stine JM, et al. Treatment of spontaneous chronic corneal epithelial defects (SCCEDs) with diamond burr debridement vs combination diamond burr debridement and superficial grid keratotomy. Veterinary Ophthalmology. 2018;21(6):622-631. https://pubmed.ncbi.nlm.nih.gov/29536611/
- McKeever F, Mitchell N, Lowe R, McAloon C. Clinical outcomes following diamond burr debridement of spontaneous chronic corneal epithelial defects: a retrospective study of 521 dogs. Veterinary Ophthalmology. 2026;29(2). https://pubmed.ncbi.nlm.nih.gov/41623201/
Changelog
- 2026-07-05: First published.
References
- Irving W, McCarthy P, Reynolds B, et al. Superficial keratectomy for the treatment of spontaneous chronic corneal epithelial defects in dogs. Veterinary Ophthalmology 2025;28(2):275-280. (2025)
- Wu D, Smith SM, Stine JM, et al. Treatment of spontaneous chronic corneal epithelial defects (SCCEDs) with diamond burr debridement vs combination diamond burr debridement and superficial grid keratotomy. Veterinary Ophthalmology 2018;21(6):622-631. (2018)
- McKeever F, Mitchell N, Lowe R, McAloon C. Clinical outcomes following diamond burr debridement of spontaneous chronic corneal epithelial defects: a retrospective study of 521 dogs. Veterinary Ophthalmology 2026;29(2). (2026)
More clinical updates
Update (July 5, 2026): Fellow-Eye Prophylaxis in Canine Primary Angle-Closure Glaucoma — 70.9% Convert Within 5 Years (Donohue 2025)
2025 cohort: 70.9% of unilateral canine PACG dogs converted in the fellow eye within 5 years; median 2.15 yr to failure, no drug class superior.
Read →Update (July 5, 2026): Injectable Platelet-Rich Plasma With Oral Omega-3 for Canine Keratoconjunctivitis Sicca (dos Santos Villa 2025 RCT)
2025 RCT: adding oral omega-3 to subconjunctival injectable PRP raised TBUT from month 3 in canine KCS; both arms lifted STT-1. Evidence summary.
Read →Update (July 5, 2026): Ocular FIP and Anterior Uveitis in the GS-441524 Era
In a 2025 case series, 1 in 3 FIP cats had ocular disease; with GS-441524, uveitis resolved in ~82% at median 44 days, but 20% got secondary glaucoma.
Read →Update (July 5, 2026): FHV-1 Dendritic Keratitis — Modified-Live Vaccine Strain Isolated From a Corneal Ulcer and the Post-Vaccination Corticosteroid Caution
A 2025 JFMS report isolated the F2 modified-live FHV-1 vaccine strain from a cat's dendritic ulcer 17 days post-vaccination — a caution against early corticosteroids.
Read →